Blood Gas and Electrolyte Analyzers Market Worldwide: Dynamics, Trends Efficiencies Forecast 2023
The global blood gas and electrolyte analyzers market was valued at $1,427 million in 2016, and is estimated to reach $2,104 million by 2023, growing at a CAGR of 5.7% from 2017 to 2023. Blood gas and electrolyte analyzers are used to measure different parameters from whole blood samples, such as pH, blood gas (pCO2 and pO2), electrolytes, and metabolites. The pH value of blood and serum or plasma is an indicator of the balance between the blood, renal (kidney), and lung (respiratory) systems, while the pCO2 value of arterial blood is used to assess efficient elimination of carbon dioxide from the body, a by-product of metabolism; and the pO2 value of arterial blood is a measure of oxygen absorbance by the body in the lungs. Electrolytes and metabolites give further information about body metabolism.
The key players profiled in the report include Radiometer Medical Aps (A Subsidiary of Danaher Corporation) (Denmark), Instrumentation Laboratory (A Werfen Company) (U.S.), Siemens AG (Germany), Roche Diagnostics Limited (Switzerland), Abbott Laboratories, Inc. (U.S.), Nova Biomedical (U.S.), OPTI Medical Systems, Inc. (A Subsidiary of Idexx Laboratories, Inc.) (U.S.), ERBA Diagnostics Mannheim GmbH (Germany), Medica Corporation (U.S.), and Alere, Inc. (U.S.).
Get Sample PDF Brochure: https://www.alliedmarketresearch.com/request-sample/4608
Asia-Pacific is considered as the top investment pocket, owing to the significant growth opportunity offered by the region. Asia-Pacific blood gas and electrolyte analyzers market is projected to grow at a highest CAGR of 7.2% during the analysis period. The growth is attributed to the rise in investment from government agencies to provide better healthcare facilities for the large patient population, increase in incidence of chronic diseases, growth in healthcare expenditure, and surge in income level of the population.
Growth in number of patients being treated in ICUs, NICUs, and emergency departmen ts; rise in patients suffering from chronic diseases; technological advancement in blood gas & electrolyte analyzers, and increase in number of product approvals are the major factors that drive the market growth. However, complexity involved in the interpretation of blood analysis data act as a restraining factor for the market growth. Increase in investment by major medical diagnostics giants and improvement in the healthcare facilities in Asia-Pacific provide growth opportunities for the market.
Geographically, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America held the leading position, owing to its well-developed healthcare industry, presence of leading blood gas & electrolyte analyzer manufacturers, and rise in number of patient’s treatment in the ICUs, NICUs, and emergency wards. Whereas, Mexico is growing at highest CAGR during the forecast period. However, Asia-Pacific is anticipated to grow at a highest growth rate with the increase in number of patients suffering from chronic diseases and rise in government initiatives for the improvement of the healthcare facilities.
Do Purchase Enquiry at : https://www.alliedmarketresearch.com/purchase-enquiry/4608